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Objectives
To assess the feasibility and uptake of a community-based prostate cancer (PCa) screening programme selecting men
according to their genetic risk of PCa. To assess the uptake of PCa screening investigations by men invited for screening.
The uptake of the pilot study would guide the opening of the larger BARCODE1 study recruiting 5000 men.
Subjects and Methods
Healthy males aged 55–69 years were invited to participate via their general practitioners (GPs). Saliva samples were
collected via mailed collection kits. After DNA extraction, genotyping was conducted using a study specific assay. Genetic
risk was based on genotyping 130 germline PCa risk single nucleotide polymorphisms (SNPs). A polygenic risk score (PRS)
was calculated for each participant using the sum of weighted alleles for 130 SNPs. Study participants with a PRS lying
above the 90th centile value were invited for PCa screening by prostate magnetic resonance imaging (MRI) and biopsy.
Results
Invitation letters were sent to 1434 men. The overall study uptake was 26% (375/1436) and 87% of responders were eligible
for study entry. DNA genotyping data were available for 297 men and 25 were invited for screening. After exclusions due
to medical comorbidity/invitations declined, 18 of 25 men (72%) underwent MRI and biopsy of the prostate. There were
seven diagnoses of PCa (38.9%). All cancers were low-risk and were managed with active surveillance.
Conclusion
The BARCODE1 Pilot has shown this community study in the UK to be feasible, with an overall uptake of 26%. The main
BARCODE1 study is now open and will recruit 5000 men. The results of BARCODE1 will be important in defining the
role of genetic profiling in targeted PCa population screening.
Patient Summary
What is the paper about?
Very few prostate cancer screening programmes currently exist anywhere in the world. Our pilot study investigated if
men in the UK would find it acceptable to have a genetic test based on a saliva sample to examine their risk of prostate
cancer development. This test would guide whether men are offered prostate cancer screening tests.
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Original Article
What does it mean for patients?
We found that the study design was acceptable: 26% of men invited to take part agreed to have the test. The majority
of men who were found to have an increased genetic risk of prostate cancer underwent further tests offered (prostate
MRI scan and biopsy). We have now expanded the study to enrol 5000 men. The BARCODE1 study will be important
in examining whether this approach could be used for large-scale population prostate cancer screening.
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Introduction
In common with other complex diseases, the genetic
heritability of prostate cancer (PCa) is composed of both rare,
high to moderately penetrant variants conferring a high risk
of disease (e.g. BRCA2 DNA repair associated [BRCA2] gene
mutations), and commonly occurring single-nucleotide
variants (SNVs) that confer risks of lower magnitude. With
the advent of the genome-wide association study (GWAS)
and the increasing numbers of cases and controls included in
such studies, PCa GWAS and meta-analyses have identified
more than 200 loci associated with PCa development [1–3].
Most of these SNVs are commonly occurring single
nucleotide polymorphisms (SNPs; i.e. minor allele frequency
[MAF] ≥5%) and although each locus is associated with a low
to moderate per allele odds ratio (OR), the genetic risk
increases with increasing number of risk alleles in a person’s
germline DNA [4]. The currently known PCa susceptibility
loci explain an estimated 34–43% of the familial relative risk
(RR) of PCa [2,3,5,6].
There are very few population PCa screening programmes
due to the lack of a test with adequate sensitivity and
specificity required for large-scale population screening. The
use of the PSA blood test was investigated in two large,
randomised screening studies: the Prostate, Lung, Colorectal
and Ovary (PLCO) study and the European Randomised
Study of Screening for Prostate Cancer (ERSPC) [7, 8].
Although long-term follow-up in the ERSPC studies has
shown a survival benefit (absolute reduction of 13 PCa deaths
per 10 000 men), the complications of prostate biopsies, high
rate of false-positive results (10% in PLCO and 18% in
ERSPC), as well as over-diagnosis of indolent PCa has led to
caution around the use of PSA testing.
Guidelines from national screening programmes such as the
United States Preventive Services Task Force (USPSTF) have
fluctuated from advising against PSA screening (in 2012) to
recommending that men make an individualised decision
regarding PSA testing in conjunction with their clinician (for
those aged 55–69 years) [9, 10]. In the UK, the National
Screening Committee recommends against universal PSA
screening.
To our knowledge, no prospective studies utilising genetic
profiling to stratify men in the population according to their
PCa risk have been performed. The use of a genetic test
utilising the known PCa risk SNPs could allow PCa screening
to be targeted to men at high risk of PCa development.
Germline DNA for genotyping requires a one-off collection,
usually in the form of a blood draw or saliva sample. Using
the genotyping data, a polygenic risk score (PRS) can be
calculated for an individual to estimate their risk of PCa
development relative to the average population risk. When
used at scale, a genotyping test is relatively cheap and can be
carried out ahead of likely disease onset to identify men with
a high PRS who may benefit from screening starting at a pre-
determined time-point. In parallel, men with a low PRS may
avoid the potential complications of invasive tests.
Utilising the known PCa risk loci, the RR of PCa for
European ancestry men in the top 1% of the PRS distribution
is 5.7 compared with the average risk of men in the general
population; this level of risk is in the range of that associated
with BRCA2 mutations [11]. For men in the top 10% of PRS
distribution the RR is 2.7 [2].
The use of PRS stratification within a PCa screening
programme has been shown through modelling studies to
reduce the level of over-diagnosis of indolent disease through
screening [12]. In the breast cancer setting, using genetics to
take a risk-stratified approach to refine screening also reduces
the rate of over-diagnosis and improves cost-effectiveness of
screening [13].
The BARCODE1 study (NCT03857477) is enrolling men of
European ancestry from the community via their GPs to
undergo a germline genetic profile test utilising 130 PCa risk
SNPs. Men in the top 10% of the study population’s genetic
risk distribution are offered screening with MRI of the
prostate followed by systematic and targeted biopsy. As the
PRS used in BARCODE1 is based on SNPs discovered in
European populations, there is a portability problem across
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different populations. Although multi-ethnic GWAS have
demonstrated that many PCa risk SNPs are shared between
populations, the risk associated with a variant may vary
according to ethnicity [3]. Additionally, some PCa risk SNPs
will be population specific. Studies are underway to
investigate the use of genetic profiling in PCa screening in
other ethnic groups [14].
The present study is the first prospective study to assess the
utility of genetic profiling in a community setting to guide
PCa screening and aims to recruit a total of 5000 men. In the
present study, we report the results of the BARCODE1 Pilot,
which was set up as a feasibility study to examine the
acceptability of the study to men in the UK community prior
to opening the main BARCODE1 study.
Subjects and Methods
Trial Design
The BARCODE1 Pilot was a feasibility study aiming to
recruit 300 participants prior to the launch of a larger trial
with 5000 participants. The study was co-ordinated and
managed by the Oncogenetics Team at The Institute of
Cancer Research, UK. Recruitment was carried out via seven
GP centres in London, and participants were invited into the
study by letter.
Eligible responders were sent a consent form to sign and
return to the study team. They were also sent a saliva
collection kit to provide a saliva sample for DNA extraction
and genotyping (Fig. 1). Participants found to lie in the top
10% of the PRS distribution were offered a MRI of the
prostate followed by prostate biopsy. Participants with
negative biopsies were followed up with annual PSA
measurement and repeat biopsies were performed if there was
a significant PSA rise (study protocol in Appendix S1).
Trial Registration
This study was reviewed by the London-Chelsea Research
Ethics Committee under reference number: 15/LO/1992 and
was approved to be conducted in NHS England by the Health
Research Authority under reference number: 147536.
Participants
The GP sites acted as recruiting centres. Practice records were
reviewed to identify men aged 55–69 years meeting study
eligibility criteria. A participant information sheet (PIS) and
health questionnaire was sent to all suitable men and
responses screened to ensure eligibility. Participants were
required to have no history of PCa, no prostate biopsy within
12 months, no contra-indications to MRI or prostate biopsy,
and to be of European ethnicity. Responders meeting the
criteria were requested to complete a postal saliva (DNA)
sample.
Sample Size
For the main BARCODE1 study, a sample size of 5000 men
will be required to identify 500 men within the top 10% of
the PRS distribution, who will undergo screening. The pilot
study was planned with the aim of recruiting 300 men, with
 30 in the top 10% of PRS distribution. This sample size
was chosen pragmatically assuming recruitment of 100 men
from each of the (initial) three GP centres. A further four
centres were added during the course of the pilot study to
complete recruitment due to a lower than anticipated
recruitment rate. All initial study procedures including
invitations to participate, informed consent and saliva
collection were carried out using the postal system.
DNA Extraction and Genotyping
DNA extraction from saliva was carried out externally by
Tepnel Pharma Services, Livingston, UK. Extracted DNA was
sent to Affymetrix (part of Thermo Fisher Scientific Inc.,
Waltham, MA, USA) for genotyping using a custom high
throughput ‘genotyping by sequencing’ assay (Eureka
myDesign Genotyping Panel; https://tools.thermofisher.com/
content/sfs/brochures/Eureka_Genotyping_Solution_datasheet.
pdf) [15]. At the time of BARCODE1 study setup, 147 index
PCa susceptibility SNPs had been reported in European
ancestry populations [2]. Our assay design aimed to capture
all of these known variants; however, 17 index SNPs could
not be successfully designed or failed quality control (QC)
using this technology, whilst a further three index variants
needed to be substituted for a suitable proxy variant to
achieve inclusion. Our final genotyping panel therefore
consisted of 130 European ancestry PCa risk SNPs
(Appendix S2). Additional QC was performed on the raw
computer assigned genotype calls, through manual






We calculated a PRS for each participant based on the sum of
risk alleles for the 130 PCa risk loci, weighted by their per-
allele log OR (formula in Appendix S2). In instances where a
variant failed genotype QC within a specific individual, to
reflect the probability of their carrying the risk allele for that
variant, missing genotype(s) were assigned a risk allele count
corresponding to the population risk allele frequency for the
variant, doubled for autosomal variants.
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The PRS mean and standard deviation (SD) for the
BARCODE1 Pilot cohort were used to calculate the PRS
threshold at the 90th centile based on a normal distribution
(Appendix S2). Using this method to calculate the 90th
centile accounts for the potential large rise in PRS value at
the extremes of the distribution in the small sample size.
BARCODE1 Pilot participants with a PRS >90th centile were
identified for PCa screening.
Screening Procedures
Participants received a letter informing them of the outcome
of genotyping and whether their PRS fell in the top 10% of
the study PRS distribution. Those found to have a PRS >90th
centile were invited to undergo PCa screening at The Royal
Marsden Hospital (RMH). Screening involved a multi-
parametric MRI scan of the prostate and a prostate biopsy.
Baseline PSA level was measured but did not alter
management. The MRI included T2-weighted, diffusion-
weighted (DW) and dynamic contrast (gadolinium)-enhanced
images. Scans were performed either at 3-T with endorectal
coil or at 1.5-T with an external phased array coil and
reported by a specialist uro-radiologist. Prostate lesions
identified were scored 1–5 according to Prostate Imaging -
Reporting and Data System (PI-RADS) as developed by the
European Society of Urogenital Radiology [16]. A score of 1
indicated clinically significant disease is highly unlikely to be
present, while a score of 5 indicated clinically significant
cancer is highly likely to be present.
The MRI was followed by prostate biopsy. A systematic 12-
core TRUS biopsy was carried out by the study urologist. If a
lesion/lesions were identified on DW-MRI, additional targeted
sampling was undertaken (Koeils UrostationTM). Prostate
biopsy samples were examined by a specialist uro-pathologist
at RMH and reported as per the 2014 International Society of
Urological Pathologists guidelines.
Outcomes
Response rates across all recruiting centres were examined, as
well as uptake of screening tests (MRI and biopsy) in men
who were invited for screening based on their PRS. Outcomes
from screening include the number of cancers diagnosed
(clinically significant and insignificant), MRI lesions detected
and biopsy-related complications.
GP screening of patient
records
Study invitation and PIS sent
to patients
Study eligibility criteria met:
-Aged 55-69 years
-No relevant medical history
to preclude prostate biopsy
-European ethnicity
-No history of prostate biopsy
in the past year
QC and analysis of genotyping
data




Top 10% of PRS
Offer MRI prostate and biopsy
Bottom 90% of PRS
End of study
Fig. 1 BARCODE1 study outline.
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An additional sub-study is ongoing to examine the
psychosocial impact of screening in this group of high-risk
individuals, the results of which will be reported separately.
Results
Study Recruitment
Recruitment to the BARCODE1 Pilot commenced in April
2016 and completed in April 2018. Initially, three GP centres
were involved. Four more sites were added to the study in
April 2017 to increase recruitment rate and complete the
pilot study.
The GPs screened the medical records of 1802 men registered
at their practices; 1436 potentially eligible men (80% of those
screened) were sent a study invitation letter, which included
the study PIS and a health questionnaire. The health
questionnaire was used to exclude men who did not meet
study eligibility criteria, as well as those with any
comorbidities that would make the risk of prostate biopsy
unacceptable.
Of the 1436 men invited to the study, 375 men responded to
the invitation letter giving a study uptake rate of 26% (range
13–47%, Table 1) of whom 329 (88%) were eligible for study
entry (Fig. 2). Reasons for exclusion from study entry
included medical comorbidities and non-European ethnicities.
Saliva collection kits were posted to 328 eligible participants
with a study consent form. A total of 307 saliva samples were
returned, giving a return rate of 94%; 21 participants
withdrew from the study after providing a saliva sample and
one withdrew prior to providing a saliva sample, giving an
overall withdrawal rate of 6.7% of eligible responders.
Participant Characteristics and Genotyping
The mean (range) age of study participants at the time of
consent was 61 (55–69) years. DNA was extracted for 303
participants whose saliva sample was returned before the cut-
off date (15 April 2018) for the pilot study. Of 303 saliva
samples that underwent DNA extraction, one sample had a
low DNA yield and could not be genotyped (further saliva
was collected later from this participant). Genotyping was
therefore carried out for 302 samples. 17 samples (5.6%)
failed QC processes due to a SNP call rate of <90%; for 12 of
these, a repeat saliva sample was subsequently returned by
the participant and passed genotyping QC. Therefore, 297
samples underwent successful genotyping. The mean
genotype call rate across the 130 SNPs for all study
participants was 99.6% and median 100% (in total 162 of
38 610 genotypes across all 297 samples failed genotyping
QC).
PRS Results
The PRS for 297 men in the BARCODE1 Pilot ranged
from 8.42 to 12.21 (median 10.34). The mean (10.33) and
SD (0.64) were used to calculate the 90th centile value,
which was 11.15 (Fig. 3). Using this threshold value, 26
participants were eligible for screening based on their PRS.
The 271 men whose PRS fell in the bottom 90% were not
eligible for screening and received standard care through
their GP.
To ensure that participants in the BARCODE1 Pilot were
representative of the general population, we compared the
PRS distribution to one calculated in another UK genotyping
dataset taken from the Prostate Testing for Cancer Treatment
(ProtecT) trial [17]. There was no significant difference in the
PRS distribution (Fig. S2; P = 0.92).
Uptake of Screening by Men in the Top 10% of PRS
Distribution
Of the 26 participants identified to be in the top 10% of
the PRS distribution, seven men did not proceed with PCa
screening: one patient died of a non-prostate-related cause
after entering the study, two were lost to follow-up, and
four withdrew when offered PCa screening. An eighth
participant underwent MRI but did not proceed to biopsy
due to persistent sterile pyuria. Therefore, the overall
uptake of PCa screening was 72% (18 of 25 living eligible
participants).
Table 1 BARCODE1 pilot study screening, response rates and saliva returns.
Site Screened, n Mail-outs, n Total responders, n (%) Eligible, n Returned saliva samples, n (% of eligible responders)
GP 1 148 148 45 (30) 45 42 (93)
GP 2 350 326 78 (24) 66 62 (94)
GP 3 277 175 23 (13) 12 12 (100)
GP 4 267 232 46 (20) 44 41 (93)
GP 5 223 211 51 (24) 49 44 (90)
GP 6 390 200 93 (47) 77 74 (96)
GP 7 145 142 37 (26) 34 30 (88)
RMH* 2 2 2 2 2
Total 1802 1436 375 (26) 329 307 (93)
GP, General Practice site. *Two participants recruited via Oncogenetics Research clinic in RMH.
© 2021 The Authors.
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Number of patients






n = 375 (26%)
Eligible
n = 329 (23%)
Saliva sample return
n = 307 (21%)
DNA extraction
n = 303 (21%)
Genetic profiling
n = 302 (21%)
PRS calculation based on
genotypes
(n = 297 (21%)
Failed QC
n = 5
Failed due to low
yield n = 1*
Saliva received after cut
off for DNA extraction
n = 4*
Withdrawal n = 22
Not eligible n = 46
Fig. 2 BARCODE1 pilot study recruitment. Percentages relate to the proportion of invitations to the study. *Saliva samples from four participants were
received after 15 April 2018, which was the cut-off date for DNA extraction in the pilot study. These participants will have DNA extracted and analysed in
the main BARCODE1 study. One saliva sample did not yield sufficient DNA at extraction and a new saliva sample was requested. This participant will
also be added to the main BARCODE1 study.
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Outcomes of PCa Screening
The MRI of the prostate (18 with endorectal coil at 3-T, one
with phased array coil at 1.5-T) followed by systematic
(targeted sampling) biopsies was carried out for 18
participants. The PSA was measured prior to MRI. The mean
(range) PSA for the 19 men undergoing MRI was 1.60 (0.3–
5.8) ng/mL.
Assigned PI-RADS scores were 1–2 in 10 participants (53%),
PI-RADS 3 in five (26%) and PI-RADS 4 in four (21%).
There were no PIRADS 5 lesions detected (Table 2).
Biopsy results were available for 18 men. One man did not
proceed to biopsy due to persistent sterile pyuria for which
he was referred for urological investigations. Table 3 displays
biopsy outcomes. All initial screening biopsies were
performed via the transrectal route except for one
(Participant 2 in Table 3), which was carried out via the
transperineal route to allow adequate sampling of small
bilateral lesions detected on MRI.
Prostate cancer was diagnosed in six of the 18 participants
(33%) who underwent an initial screening biopsy; four of these
had a target lesion identified on MRI (three PI-RADS 4 lesions
and one PI-RADS 3 lesion), while four participants with
identified target lesions (three PI-RADS 3 and one PI-RADS 4)
were negative on biopsy. The mean maximum cancer core
length (MCCL) in the four MRI-identified lesions was 1.2 mm
with a mean pre-biopsy PSA level of 1.6 ng/mL, and in the
two cancers not identified on MRI, the mean MCCL was
1 mm with a mean pre-biopsy PSA level of 1.1 ng/mL.
In the remaining 12 participants, two were diagnosed with
atypical small acinar proliferation (ASAP) and high-grade
prostatic intraepithelial neoplasia (HGPIN); a repeat MRI and
biopsy was carried out for both at 6 months as per trial
protocol. The participant with ASAP was diagnosed with
Gleason 3 + 4 PCa (MCCL 1.5 mm, 1%) and the participant
with HGPIN had benign findings. All cancers were discussed
in the RMH uro-oncology multidisciplinary team meeting
and management by active surveillance (AS) was
recommended for all seven cases (Table 4).
Incidental Findings and Post-Biopsy Complications
There was one case of an incidental finding reported on MRI
of the prostate that required further investigation, resulting in
a diagnosis of low-grade B-cell non-Hodgkin lymphoma. An
uncomplicated lower urinary tract infection was diagnosed in
two out of 18 men (11%) who underwent a prostate biopsy.
Both cases were managed successfully with oral antibiotics.
There were no other post-biopsy complications.
Post-Biopsy Follow-Up
Men diagnosed with PCa in this pilot study (seven; six
initially and one at follow-up) are currently undergoing
follow-up in the RMH uro-oncology clinic. For the 11
participants who had a benign biopsy result, study follow-up
8 9 10 11














































Fig. 3 PRS distribution in BARCODE1 Pilot. (A) The dashed line denotes the 90th centile PRS value (11.15). (B) Boxplot of the PRS distribution in BARCODE1
pilot displaying minimum and maximum values of PRS in whole study cohort as well as outliers. The dashed line denotes the 90th centile PRS value
(11.15).
Table 2 Distribution of PI-RADS score in 19 men who underwent MRI
prostate in BARCODE1 pilot.
PI-RADS Score MRI, n (%) Number of repeat MRI
1 2 (11) 0
2 8 (42) 2
3 5 (26) 0
4 4 (21) 0
5 0 0
Total 19 2
Two scans repeated due to initial findings of ASAP and HGPIN on first
biopsy. PI-RADS score was unchanged as both had a score of 2 on
first and second scans.
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will continue with annual PSA measurement for at least
5 years with repeat MRI and biopsy if the PSA rises above
the protocol set threshold for repeat biopsy. Cancer registries
will be reviewed, and data will be collected for all men
enrolled in the study for a minimum of 10 years to determine
cancer incidence and mortality.
Discussion
The BARCODE1 Pilot was successful in demonstrating the
acceptability and feasibility of community-based PCa
screening guided by germline genetics in the UK. There was
good uptake by men invited by their GPs, and a high level of
interest from primary care centres wishing to participate after
the pilot transitioned to the larger main study. Uptake of PCa
screening by men offered it was 72%, which is comparable to
the uptake of national screening programmes such as the
bowel and breast cancer screening programmes in England
(59–72%) [18, 19].
The BARCODE1 main study has now commenced
recruitment with the aim of genotyping 5000 men in the
community and in turn, offer screening to those lying in
the top 10% of the PRS distribution. The PRS threshold
for screening within BARCODE1 was chosen pragmatically
so as to lead to a feasible number of men that could be
offered screening procedures within the study. It was also
guided by the latest scientific estimates that men of
European ancestry with a PRS between the 90th and 99th
centiles have a 2.7-fold higher risk of developing PCa
compared with the population average. This is similar to
the PCa risk of a man with a first-degree family history
and for whom guidance advises PCa screening is
considered [20].
Table 4 Features of prostate cancers diagnosed in pilot study.
Number of biopsies carried out Gleason score on final biopsy MCCL, mm TCCL, mm
Participant 1 1 3 + 3 1 2
Participant 2 1 3 + 3 2 2
Participant 3 1 3 + 3 1 1
Participant 4 2 3 + 3 1 1
Participant 5 1 3 + 3 1 1
Participant 6 1 3 + 3 0.5 0.5
Participant 7 2 3 + 4 1.5 2
TCCL, total cancer core length.




















62 0.78 4 3 + 3 AS 12.12
66 5.8 4 3 + 3 AS 11.19
66 2.3 3 3 + 3 AS 11.32
55 2.4 1 3 + 4 AS 2 3 + 3 AS 11.17
56 1 2 3 + 3 AS 11.53
64 3.6 4 3 + 3 AS 11.31
64 0.64 2 ASAP Repeat MRI
and Bx at
6 months
2 3 + 4 AS 11.42
55 0.35 2 HGPIN Repeat MRI
and Bx at
6 months
2 Benign Trial f/u 11.32
56 2.6 2 Benign Trial f/u 11.49
59 0.89 4 Benign Trial f/u 11.38
60 0.46 3 Benign Trial f/u 11.17
56 0.89 2 Benign Trial f/u 11.69
56 0.3 2 Benign Trial f/u 11.32
59 1.5 1 Benign Trial f/u 11.53
60 0.93 3 Benign Trial f/u 11.73
55 0.41 2 Benign Trial f/u 12.21
66 1.7 2 Benign Trial f/u 11.49
59 1.8 3 Benign Trial f/u 11.44
Bx, biopsy; f/u, follow-up. Participant 4 underwent an MRI prostate and transperineal template biopsy as part of the local AS protocol and the
Gleason score was downgraded on the second biopsy to 3 + 3. Patients 7 and 8 underwent a repeat MRI and biopsy as part of the pilot study,
6 months after initial biopsy due to findings of ASAP and HGPIN, respectively.
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A 26% study uptake rate by invitees was comparable to the
PROFILE pilot screening study reported by our team in 2016
[21], which had an uptake of 12.8% in men with a family
history of PCa. The uptake in the BARCODE1 Pilot was
lower than that reported in the ProtecT [17] study that
invited participants via their GPs for PSA-based screening
and had an uptake of 36%. This may partly be explained by
one of the GP sites in our present study having a large
proportion of patients of non-European ethnicities (in
keeping with the local population demographic) who were
not eligible for study entry; unfortunately, patient ethnicity is
not recorded routinely at some practices therefore some study
invitations would have been sent to men who were not
eligible and therefore would not have responded to the study
invitation. To offset the lower than expected uptake, an
additional four GP sites opened recruitment, and for the
main study a large network of over 70 GP sites will be
recruiting. By expanding the main study to a large number of
GPs and with modifications in response to participants’
feedback, such as reducing the size of the information pack
sent out with study invitations, we may find that uptake
increases in the main BARCODE1 study.
In the present pilot, 39% (seven of 18) of men screened were
diagnosed with low Gleason grade (Gleason 3 + 3 or 3 + 4),
low-stage (no nodal involvement on imaging) PCa amenable
to management by AS. The rate of progression to disease that
requires treatment could not be evaluated because of the
short follow-up in the pilot phase of the study (mean [range]
4.5 [1–11] months). Management with AS (regular PSA tests,
interval MRI scans and repeat biopsies), although resource
intensive, potentially offers early curative treatment options in
this high-risk relatively young population.
The PRS used in BARCODE1 includes 130 PCa risk SNPs
that associate with both aggressive and non-aggressive PCa.
There have been no risk loci identified to date that are
specific to aggressive PCa. Despite the lack of predictive
biomarkers for aggressive disease, a recent pan-ancestry meta-
analysis of PCa GWAS data found that approximately a third
of aggressive PCa cases occurred in men whose genetic risk
lay in the top 10% of the risk distribution [3]. Therefore,
using a PRS-based approach to target screening could identify
a subset of men in the population in which a substantial
proportion of aggressive PCa cases will develop. The results
of the larger BARCODE1 study and long-term follow-up will
examine this further.
Apart from identifying men at risk of PCa, some of whom
will develop aggressive disease, utilising a PRS for PCa
screening may reduce the level of over-diagnosis of indolent
disease that has prevented the adoption of PSA-based
population screening [22]. Over-diagnosis is defined as the
‘detection by screening of tumours that would not have
presented clinically in a person’s lifetime in the absence of
screening’ [12]. In the context of PSA-based PCa screening,
the proportion of over-diagnosed cases has been shown to be
inversely proportional to PRS [12]. In a retrospective analysis
of a PCa PRS in 17 000 men in the UK, there was a 56%
reduction in over-diagnosis between the lowest and highest
PRS quartiles when using PSA for screening. Therefore,
utilising a PRS as part of a programme to target screening to
men in the top quartile or upper decile of the genetic risk
distribution has the potential to reduce over-diagnosis
compared with unselected PSA screening. This in turn would
spare men at low genetic risk from undergoing screening
procedures [12, 23, 24].
Although over-diagnosis is unavoidable in most screening
programmes, attempts to minimise this by utilising a targeted
approach based on genetic risk while still balancing the
identification of high-risk cancers will be investigated in the
BARCODE1 study. Although all the cancers diagnosed in the
pilot study were low grade, data from the full BARCODE1
study are needed to draw conclusions on the effect of PRS-
based screening on over-diagnosis. With the increased
acceptability and safety of using AS, study participants whose
low-grade PCa does not progress can avoid the complications
of radical treatment while those who experience disease
progression can be treated promptly.
As the BARCODE1 study PRS is based on SNPs identified in
European populations, study recruitment was restricted to
men of European ethnicity. Dedicated studies in populations
of other ethnicities are in progress to establish population-
specific genotyping panels and thresholds for PCa screening.
In a recent multi-ancestry PCa GWAS meta-analysis reported
by Conti et al. [3], case-control data was analysed from
European, African and East Asian ancestry men. That
analysis confirmed that many PCa loci are shared across
populations, although the risk associated with PRS varied
between populations. The absolute risk of PCa in men lying
in the top decile of the genetic risk distribution was highest
in men of European and African ancestry at 38%, while the
top decile in East Asian ancestry men had the lowest risk of
26%. Identifying this ancestry-related variation in genetic risk
will be useful in the development of tailored approaches to
PCa risk assessment in different populations [3]. In this vein,
one of the screening arms in the ongoing PROFILE screening
study (NCT02543905) is recruiting men of African and Afro-
Caribbean ancestry to investigate the relationship between a
genetic profile and outcome at prostate biopsy during
screening. Several international efforts are also trying to
identify ethnic-specific risk SNPs and assess generally the
utility of the polygenic risk scores currently in use [3, 25].
These will help guide the development of a cross-ethnic PCa
screening programme in diverse populations [26–28].
The BARCODE1 study is the first prospective study to utilise
a germline SNP profile to target PCa screening in a
© 2021 The Authors.
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community-based setting. The STOCKHOLM3 (STHLM3)
study [29], reported in 2015, was the first large prospective
and population-based PCa screening study that assessed a
targeted approach to screening. The study utilised a screening
model combining plasma protein biomarkers (including PSA),
232 risk SNPs and a set of defined clinical variables (e.g. age,
family history) and compared this with PSA measurement
alone (≥3 ng/mL) [29]. Although the sensitivity for the
detection of high-risk PCa was significantly improved with
the STHLM3 model (area under the curve 0.74 vs 0.56), the
value of the SNP profile within the larger model was difficult
to ascertain. Since that study was reported, the STHLM3
model has been combined with MRI targeted biopsies in a
prospective study comparing it with PSA screening and
reported a 69% reduction in over-diagnosis while maintaining
the sensitivity for the detection of significant PCa [30]. By
examining the role of targeting screening using only a
germline SNP profile in BARCODE1, the contribution of a
PRS in such multi-factor models can be evaluated and guide
the future design of screening programmes that may use a
SNP profile alongside other biomarkers and/or imaging. By
carrying out a biopsy for all men who undergo a MRI of the
prostate (as well as PSA test), the utility of MRI as a
screening tool for men at increased genetic risk of PCa will
be investigated in BARCODE1. To date, the usefulness of
pre-biopsy MRI has been reported in men with an elevated
PSA in studies such as the PROstate MRI Imaging Study
(PROMIS) and PRECISION [31, 32]. By correlating the
results of MRI and biopsy in the  500 men screened in
BARCODE1, we aim to define the role of MRI in guiding the
decision to undergo a prostate biopsy in men with an
increased genetic risk of PCa.
Additional studies are required to establish the role of MRI
outside and within the context of genetic risk. The
ReIMAGINE Prostate Cancer Screening study
(NCT04063566) is currently inviting PSA na€ıve men aged 50–
75 years via their GP to undergo MRI of the prostate. Those
with lesions assigned a PI-RADS score of 3–5 (or with a
suspicious PSA density >0.12 ng/ml2) will be referred for
prostate biopsy. In the sister study, ReIMAGINE Prostate
Cancer Risk (NCT04060589), participants accepting a biopsy
based on their study MRI will be invited to donate samples
including germline DNA, which will be genotyped to
retrospectively assess polygenic risk. The BARCODE1 study
and complimentary studies such as ReIMAGINE will allow a
robust assessment of different screening modalities and
provide valuable information to guide the application of less
invasive screening methods, and potentially plan for precision
PCa screening in the population.
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